Meta AnalysisID 4353
羟乙基淀粉130/0.4用于手术患者容量替代治疗的系统评价和Meta分析
CRD42020173058
The purpose of this systematic review is to determine the effect of hydroxyethyl starch 130/0.4 on volume replacement therapy in surgical patients.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4353
- Evidence Id
- 12911
- Core Evidence Id
- 12911
- Source Meta Analysis Id
- 4320
- Herb2 Meta Analysis Id
- HBMA004320
- Crd Id
- CRD42020173058
- Title
- Hydroxyethyl starch 130/0.4 for volume replacement therapy in surgical patients: a systematic review and meta-analysis
- Review Question
- The purpose of this systematic review is to determine the effect of hydroxyethyl starch 130/0.4 on volume replacement therapy in surgical patients.
- Study Type Included
- Randomized controlled trials (RCTs).
- Condition Being Studied
- More than 230 million major surgical procedures are performed annually, and a large proportion of surgical patients will undergo fluid replacement therapy perioperatively to maitain extracellular fluid volume. As is known to all, colloids remain intravascular longer than crystalloids, thereby improving microcirculation perfusion, promoting hemodynamic stability, and avoiding tissue edema. Furthermore, hydroxyethyl starch (HES) solutions are commonly used semisynthetic colloids for fluid resuscitation in patients undergoing major surgery. However, the use of HES solutions, particularly high-molecularweight and molar substitution ratios, is associated with increased rates of death, coagulopathy, and kidney dysfunction. A modern, third-generation HES product with lower molecular weight and lower molar substitution rarios (ie.6% HES 130/0.4) may be related to less renal or coagulation side effects than older congeners, but its perioperative safety and efficacy is unclear. Therefore, the purpose of this systematic review and meta-analysis is to evaluate the clinical effect of HES 130/0.4 on postoperative mortality and the incidence of kidney complications in adult surgical patients.
- Participant
- Inclusion criteria: Trials that included adult patients (18 yr or older) who have undergone surgery. Exclusion criteria: Trials that included patients scheduled for any type of transplant surgery, burns or trauma surgery
- Animal
- Human Disease Modelled
- Intervention
- We will include trials that evaluated perioperative administration of hydroxyethyl starch 130/0.4 in surgical patients.
- Comparator Control
- We will include trials that compared hydroxyethyl starch 130/0.4 to any other liquid.
- Main Outcome
- The primary outcome will be postoperative mortality (within 30 days after surgery). Measures of effect relative risks
- Outcome Measure
- Additional Outcome
- The secondary outcomes will include incidence of postoperative author-defined acute kidney injury (AKI) and requirement for renal replacement therapy (RRT). Measures of effect relative risks
- Study Method
- Systematic review
- Keyword
- Hormone Replacement Therapy; Humans; Hydroxyethyl Starch Derivatives; Plasma Substitutes
- Contact
- Hai Yu [email protected]
- Organisational Affiliation
- West China Hospital, Sichuan University
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Completed not published
- First Submission Date
- 2020-03-10
- Registration Date
- 2020-04-28
- Anticipated Start Date
- 2020-03-11
- Anticipated Completion Date
- 2020-06-30
- Title Cn
- 羟乙基淀粉130/0.4用于手术患者容量替代治疗的系统评价和Meta分析
- Title En
- Hydroxyethyl starch 130/0.4 for volume replacement therapy in surgical patients: a systematic review and meta-analysis
- Bilingual Status
- complete